Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Chunlan Zheng"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Tuberculosis (TB), caused by the bacterial pathogen Mycobacterium tuberculosis (MTB), remains one of the most prevalent and deadly infectious diseases worldwide. Currently, there are complex interactions between host cells and pathogens in TB. The on
Externí odkaz:
https://doaj.org/article/73a74a5401d84140bcf4e02407f75e84
Publikováno v:
JMIR Public Health and Surveillance, Vol 10, p e53948 (2024)
BackgroundDiabetes mellitus (DM) increases the risk of developing tuberculosis (TB), and optimal glycemic control has been shown to reduce the risk of complications and improve the TB treatment outcomes in patients with DM. ObjectiveThis study aims
Externí odkaz:
https://doaj.org/article/db9afea11ea54e3d9c5c16569fa010f3
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
Tuberculosis (TB) is caused by the bacterial pathogen Mycobacterium tuberculosis (MTB) and is one of the principal reasons for mortality and morbidity worldwide. Currently, recommended anti-tuberculosis drugs include isoniazid, rifampicin, ethambutol
Externí odkaz:
https://doaj.org/article/5a2dd72b7e4144e4a661feb5d0ae95b8
Publikováno v:
Asian Journal of Surgery, Vol 46, Iss 10, Pp 4677-4678 (2023)
Externí odkaz:
https://doaj.org/article/af3c2e98a1b4407c838eb48c9ba5a3ee
Autor:
Xiang Jiang, Yanan Peng, Lan Liu, Youwei Wang, Mengting Li, Wenjie Li, Fengxing Huang, Chunlan Zheng, Fei Xu, Qian Hu, Wanhui Wei, Shouquan Dong, Qiu Zhao
Publikováno v:
Liver International. 42:2743-2758
Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that display a critical role in various liver diseases. However, the role of MAIT cells in cholestatic liver fibrogenesis remains obscure. Our study aims to assess the contributi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9b790970254ca39f960c64825651ee2
https://doi.org/10.1111/liv.15445
https://doi.org/10.1111/liv.15445
Autor:
Wenwen Wang, Hongjun Guo, Shengyu Wu, Shuyuan Xian, Weiwei Zhang, Ruitao Zhang, Zhihua Chen, Ke Su, Ying Zhang, Ying Zhu, Danxia Chu, Mengling Zhao, Zhihua Tang, Chunlan Zheng, Zongqiang Huang, Qian Ma, Ruixia Guo
Publikováno v:
Reproductive Sciences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1620c6146c6e1e23369ec20a6fb83f45
https://doi.org/10.1007/s43032-023-01231-x
https://doi.org/10.1007/s43032-023-01231-x
Autor:
Wenwen Wang, Hongjun Guo, Shengyu Wu, Shuyuan Xian, Weiwei Zhang, Ruitao Zhang, Zhihua Chen, Ke Su, Ying Zhang, Ying Zhu, Danxia Chu, Mengling Zhao, Zhihua Tang, Chunlan Zheng, Zongqiang Huang, Qian Ma, Ruixia Guo
Publikováno v:
Reproductive Sciences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57539f0f573216c049db03c7c63749e0
https://doi.org/10.1007/s43032-022-01134-3
https://doi.org/10.1007/s43032-022-01134-3
Publikováno v:
Pharmacogenomics and Personalized Medicine.
Chunlan Zheng,1,2,* Yanan Peng,1,2,* Haizhou Wang,1,2 Youwei Wang,1,2 Lan Liu,1,2,* Qiu Zhao1,2,* 1Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Peopleâs Republic of China; 2Hubei Clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5c8c76edd5854dd5c36623f81096afd
https://www.dovepress.com/identification-and-validation-of-ferroptosis-related-subtypes-and-a-pr-peer-reviewed-fulltext-article-PGPM
https://www.dovepress.com/identification-and-validation-of-ferroptosis-related-subtypes-and-a-pr-peer-reviewed-fulltext-article-PGPM
Publikováno v:
Global Health Action, Vol 10, Iss 1 (2017)
Background: The double burden of tuberculosis (TB) and diabetes mellitus (DM) is hitting certain Asian countries harder than other areas. In a global estimate, 15% of all TB cases could be attributable to DM, with 40% of those cases coming from India
Externí odkaz:
https://doaj.org/article/8ed85d2073fd4e9281db79e49ce0401b
Publikováno v:
Drug Design, Development and Therapy
Rifapentine is a rifamycin derivate approved by the US Food and Drug Administration in 1998 for the treatment of active, drug-susceptible tuberculosis (TB). In 2014, rifapentine was approved for the treatment of latent TB infection in patients at hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60282aa813282fc68742491c0a1e7368
https://doi.org/10.2147/dddt.s146506
https://doi.org/10.2147/dddt.s146506